Pharmacists warning of hay fever 'cure' that could pose 'serious health risk'
The organisation, which represents more than 6,000 community pharmacies across the country, said it was concerned that medication from unregulated sites could be fake and pose a risk to patient safety.
It added that health staff have been receiving more and more enquiries about Kenalog in recent weeks.
(Image: Andrew Matthews/PA Wire)
The drug also has known side-effects, such as increased blood pressure, dizziness, severe abdominal pain, depression and mood swings.
Kenalog is a prescription-only medicine that is not licensed for the treatment of hay fever in the UK.
It contains triamcinolone acetonide, which is a steroid injection licensed for a number of conditions such as arthritis, but not for hay fever.
In 2022, the regulator the Medicines and Healthcare products Regulatory Agency (MHRA) and the Committees of Advertising Practice (CAP) issued a joint enforcement notice about the advertising of Kenalog injections.
They told all organisations offering Kenalog as a hay fever treatment to stop advertising it on any of their social media or website advertising.
The NPA said some of the medication being sold online is fake, could be swapped for other medication, or does not meet UK safety and quality standards.
Its snapshot survey of over 350 pharmacies found 45% have recently had queries from patients about using Kenalog as a treatment for hay fever.
Most (96%) had also seen a significant increase in patients seeking help for hay fever symptoms since the start of April. Recommended Reading:
Olivier Picard, chairman of the National Pharmacy Association, said: 'We know that hay fever season is well and truly upon us and as these findings show, pharmacies are reporting increased numbers of patients visiting them to help treat their symptoms.
'Kenalog is not licensed in the UK for the treatment of hay fever and we are clear that patients should not seek it online or request it from their community pharmacy.
'We're urging people to avoid using unlicensed treatments, which could pose a serious risk to their health, and instead speak with their pharmacist about other options for managing hay fever symptoms.
'Pharmacists are well placed to provide safe licensed alternatives, such as antihistamines or steroid nasal sprays.
'Medication from unregulated sellers could be fake, swapped for an alternative medication and not meet rigorous safety standards we have in the UK.
'Instead, patients experiencing hay fever should visit their local pharmacy on their doorstep, who can quickly and safely provide treatments to relieve their symptoms.
'If people are unsure about medication bought online, they should check with their pharmacist.'
The NPA is also urging regulators to reintroduce rules that made it mandatory for a list of regulated online UK medicine sellers to be made publicly available.
Previous EU rules required this to happen, but these were scrapped when the UK left the EU.
The NPA argues patients should be able to easily identify a regulated online pharmacy and avoid sellers who are not regulated in the UK.
Mr Picard said reintroducing the previous rules would 'provide a helpful tool for patients to understand how to find a regulated, safe online pharmacy'.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Metro
a day ago
- Metro
Man's deadly brain cancer disappears after experimental drug trial
Chloe Johnson Published July 23, 2025 4:47pm Link is copied Comments Ben Trotman, 43, was diagnosed with glioblastoma, an aggressive form of brain cancer where patients typically die within 12-to-18 months, in October of 2022. Now, however, he is showing no signs of the disease after being administered the immunotherapy drug ipilimumab (Picture: Marie Mangan/UCLH/PA Wire) Two months are receiving ipilimumab, Trotman married his wife Emily and, in April 2025, they welcomed their daughter, Mabel. At the time of diagnosis, a family friend recommended that Trotman should be referred to The National Hospital for Neurology and Neurosurgery at UCLH, where they met consultant medical oncologist Dr Paul Mulholland. Mulholland recruited Trotman to a clinical trial he was running, in which Trotman would be the first in the world to receive the immunotherapy drug ipilimumab to treat glioblastoma prior to standard treatment. Now aged 43 - two years and eight months on from having this treatment - Ben's scans are clear with no signs of tumour (Picture: UCLH) Trotman's wife, Emily, said: 'Getting this diagnosis was the most traumatic experience. We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live. Had we not met Dr Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation' (Picture: Marie Mangan/UCLH/PA Wire) Now, a new immunotherapy trial for this deadly form of cancer is now set to enrol 16 people over an 18-month period, following the remarkable outcome which saw Trotman's tumour vanish. The NHS study has been established in memory of Baroness Margaret McDonagh, who succumbed to the disease. Dame Siobhain McDonagh MP, sister to the Baroness, led a fundraising campaign to raise more than £1 million to cover the costs of the new trial. Patients diagnosed with glioblastoma will receive the immunotherapy drug ipilimumab prior to standard treatment, building on a previous study involving the same drug (Picture: Getty) Dame McDonagh, MP for Mitcham and Morden and chair of the all-party parliamentary group on brain tumours, said: 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma. Changing this was Margaret's final campaign and one that I have continued in her memory. I am so grateful to the many people who knew and respected Margaret, who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial' (Picture: Marie Mangan/UCLH/PA Wire) Consultant medical oncologist, Dr Paul Mulholland, who is leading the new trial, said of Ben's recovery: 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumour that was initially visible on scans. We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumour at bay – and it has so far, which we are delighted to see' This new treatment will be administered at the NIHR UCLH's Clinical Research Facility and the National Hospital for Neurology and Neurosurgery. The patients will receive the drug ipilimumab before proceeding to standard treatments that may include surgery, radiotherapy and chemotherapy. Mulholland said of the trial: 'The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy' (Picture: Getty) Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.
Scotsman
5 days ago
- Scotsman
New AI tool could speed up skin cancer diagnoses in remote parts of world
Technology would enable early detection without the need for direct access to dermatologists Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... A researcher at a Scottish university has developed AI tools that could give people in remote areas of the world access to fast and potentially life-saving skin cancer diagnoses. Tess Watt , the PhD student at Heriot-Watt University in Edinburgh who led the project to develop the technology, said it is intended to enable early detection of skin conditions anywhere in the world, and without the need for direct access to dermatologists. The technology also works without internet access. Advertisement Hide Ad Advertisement Hide Ad PhD student Tess Watt, who has developed AI tools that could give people in remote areas of the world access to fast and potentially life-saving skin cancer diagnoses | Heriot-Watt University/PA Wire The system involves a patient taking a photograph of their skin complaint using a small camera attached to a Raspberry Pi device - a cheap, energy-efficient handheld computer that is capable of storing vast amounts of information. The photograph is analysed in real-time using the latest state-of-the-art image classification, comparing it to an enormous dataset of thousands of images stored on the device to reach a diagnosis. The findings are then shared with a local GP service to begin a suitable treatment plan. Advertisement Hide Ad Advertisement Hide Ad The project is understood to be the first of its kind to combine AI medical diagnosis with the aim of serving remote communities. Ms Watt explained: "Healthcare from home is a really important topic at the moment, especially as GP wait times continue to grow. "If we can empower people to monitor skin conditions from their own homes using AI, we can dramatically reduce delays in diagnosis." A prototype of the device has already been demonstrated at Heriot-Watt's advanced health and care technologies suite. Advertisement Hide Ad Advertisement Hide Ad Up to 85 per cent accurate The research team said the tool is up to 85 per cent accurate in its diagnostic capabilities, but they hope to increase this further by gaining access to more skin lesion datasets, aided by advanced machine tools. Ms Watt is also in talks with NHS Scotland to begin the ethical approval process for testing the technology in real-world clinical settings. "Hopefully in the next year or two, we'll have a pilot project under way," she said, noting medical technology often takes years to move from prototype to implementation. Advertisement Hide Ad Advertisement Hide Ad She added: "By the time I finish my PhD, three years from now, I'd love to see something well into the pipeline that's on its way to real-world use." The university said the long-term vision is to roll the system out first across remote regions of Scotland , before expanding to global areas with limited access to dermatological care. It added the technology could also offer vital support to patients who are infirm or unable to travel, allowing loved ones to assist with capturing and submitting diagnostic images to GPs. Advertisement Hide Ad Advertisement Hide Ad Ms Watt's academic supervisor, Dr Christos Chrysoulas , said: "E-health devices must be engineered to operate independently of external connectivity to ensure continuity of patient service and safety. "In the event of a network or cloud service failure, such devices must fail safely and maintain all essential clinical operations without functional degradation. "While auxiliary or non-critical features may become temporarily unavailable, the core diagnostic and even therapeutic capabilities must remain fully operational, in compliance of course with safety and regulatory requirements.
Scotsman
15-07-2025
- Scotsman
Ambulance staff being 'pushed beyond breaking point' as 2.7m hours of overtime revealed
A warning has been issued that the ambulance service is being 'kept afloat' by staff overtime Sign up to our Politics newsletter Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Scottish ambulance staff have worked more than 2.7 million hours of overtime, costing taxpayers almost £74 million - with concerns raised the pressures are 'pushing already exhausted staff beyond breaking point'. The statistics come amid separate analysis of cancer waiting times showing patients waited a year for treatment to begin and a warning from a senior doctor that 'the Scottish NHS is struggling to provide the care patients need, when they need it'. Advertisement Hide Ad Advertisement Hide Ad Ambulance staff are working large amounts of overtime Picture: Jane Barlow/PA Wire New statistics revealed under freedom of information legislation, showed 2,718,922 hours of overtime were worked by paramedics, ambulance technicians, care assistants and specialist nurses between 2020 and 2024. The figure peaked in 2022, when 581,155 overtime hours were worked. While 2023 was the highest year for overtime spend, costing just shy of £15.7 million. Figures for 2023 and 2024 also assess how many required hours in the ambulance service are filled by staff working overtime. For those years, the proportion was 24 per cent and 23 per cent respectively. Advertisement Hide Ad Advertisement Hide Ad Services 'kept afloat' by overtime Scottish Conservative health spokesman, Dr Sandesh Gulhane, said the situation was 'completely unacceptable',and claimed the ambulance service was being 'kept afloat' by overtime. Conservative MSP Dr Sandesh Gulhane He added: 'This will be pushing already exhausted staff beyond breaking point and is completely unsustainable. 'Relying on overstretched staff to plug gaps in shift will be putting staff as well as patients at serious risk. 'Ambulance crews have been left dangerously understaffed because of years of dire workforce planning by successive SNP health secretaries who are clueless to the scale of the emergency facing them.' Advertisement Hide Ad Advertisement Hide Ad The NHS, Dr Gulhane said, is in a 'state of permanent crisis'. A spokesman for the Scottish Ambulance Service said: 'Our staff do a fantastic job helping patients and saving lives across Scotland each and every day. Advertisement Hide Ad Advertisement Hide Ad 'To support them, over the last three years, we've recruited a record 1,388 staff, introduced 52 additional ambulances, aligned shift patterns to meet patient demand and expanded into 10 new locations as part of our demand and capacity programme. 'Since the recruitment of the additional staff we have seen a reduction in total overtime hours despite significant issues at some hospital sites in relation to turnaround times. 'As with all ambulance services across the UK, we offer overtime to boost shift cover during periods of increased pressure and high demand, and we continue to monitor spend.' Long cancer waits revealed Separate analysis from the Scottish Lib Dems has revealed the longest waits for first treatment of cancer, with patients waiting up to a year. Advertisement Hide Ad Advertisement Hide Ad The party analysed waiting times from an urgent referral with suspicion of cancer to first treatment for patients in every health board - with an NHS Lothian patient forced to wait 393 days for treatment in the quarter ending March 2025. In the same period, patients in Grampian, the Borders, and Dumfries and Galloway waited 11 months for treatment to begin. Between the quarter ending March 2015 and March 2025, the longest wait in NHS Borders has more than quadrupled, increasing from 76 days to 343 days. Advertisement Hide Ad Advertisement Hide Ad Over the same period, the longest wait in NHS Dumfries & Galloway has more than trebled, from 99 days to 347 days and since March 2015, the longest waits in NHS Ayrshire & Arran, NHS Orkney and NHS Shetland have more than doubled. Last month, SNP Public Health Minister Jenni Minto admitted that people could be dying as a result of later cancer diagnoses. Scottish Lib Dems leader, Alex Cole-Hamilton, said: 'All across Scotland, the SNP government isn't giving cancer patients the best chance of survival. These statistics show huge increases in waiting times to begin treatment after an urgent referral with suspicion of cancer, stretching up to a year. Scottish Liberal Democrats leader Alex Cole-Hamilton | PA 'International studies show Scotland falling behind. The fact that SNP ministers are now admitting that their failures may have caused people to die shows just how badly they have got this wrong. Advertisement Hide Ad Advertisement Hide Ad 'Access to screening programmes, diagnoses and treatment is a postcode lottery across the country.' NHS 'underinvestment' fears Dr Alan Robertson, chair of BMA Scotland's consultant committee, said the 'worrying statistics' reflect 'our continued warnings about how badly the Scottish NHS is struggling to provide the care patients need, when they need it'. He added: 'At the heart of this are years of underinvestment and a consistent failure to plan for the future, which means the NHS in Scotland is struggling to deliver what is required with current resources. We know there are still more than 1,000 WTE consultant vacancies across Scotland, and so this raises questions about how these types of waits will be tackled when there are not enough consultants to keep up with current demand. READ MORE: Cancer patients forced to pay for private treatment amid NHS delays Advertisement Hide Ad Advertisement Hide Ad 'Unfortunately there is no overnight solution, but steps must be taken now to value and retain the doctors the NHS does have, as part of finally drawing up a proper long term workforce plan for the NHS. Without that plan, and urgent reforms, there is little chance of waiting times like these improving anytime soon.' SNP Health Secretary, Neil Gray, said: 'We know that some people are still waiting too long to begin their cancer treatment, and that is not acceptable. We are determined to improve waiting times and ensure everyone gets the timely care they deserve. Health Secretary Neil Gray. Picture: Andrew Milligan 'It's disappointing that the 31-day standard was narrowly missed this quarter. However, performance has remained steady at around 95 per cent since the pandemic. The median wait for treatment is three days, and the median wait from urgent suspicion of cancer referral to treatment is 52 days, demonstrating the extensive work by staff across Scotland to treat people as quickly and effectively as possible. 'We are treating more patients with cancer on time, within both standards, compared to the same quarter six years ago – 7.7 per cent more within the 31-day standard & 0.1 per cent more within the 62-day standard.' Advertisement Hide Ad Advertisement Hide Ad
